6.85
0.00 (0.07%)
| Penutupan Terdahulu | 6.84 |
| Buka | 6.78 |
| Jumlah Dagangan | 1,044,744 |
| Purata Dagangan (3B) | 4,303,160 |
| Modal Pasaran | 1,112,305,536 |
| Harga / Pendapatan (P/E TTM) | 3.41 |
| Harga / Jualan (P/S) | 1.04 |
| Harga / Buku (P/B) | 41.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | 38.14% |
| Margin Operasi (TTM) | 77.40% |
| EPS Cair (TTM) | 2.75 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 610.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 179.90% |
| Nisbah Semasa (MRQ) | 2.06 |
| Aliran Tunai Operasi (OCF TTM) | -189.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 61.88 M |
| Pulangan Atas Aset (ROA TTM) | 19.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Novavax, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -4.0 |
| Purata | -0.50 |
|
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 8.78% |
| % Dimiliki oleh Institusi | 57.19% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Shah Capital Management | 30 Sep 2025 | 11,811,780 |
| Tsp Capital Management Group, Llc | 30 Sep 2025 | 1,399,065 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 18.00 (Cantor Fitzgerald, 162.97%) | Beli |
| Median | 11.00 (60.70%) | |
| Rendah | 6.00 (JP Morgan, -12.35%) | Jual |
| Purata | 11.60 (69.47%) | |
| Jumlah | 3 Beli, 1 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 7.61 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 18 Nov 2025 | 6.00 (-12.34%) | Jual | 6.57 |
| B. Riley Securities | 10 Nov 2025 | 16.00 (133.75%) | Beli | 7.11 |
| TD Cowen | 04 Nov 2025 | 7.00 (2.26%) | Pegang | 7.51 |
| Cantor Fitzgerald | 24 Oct 2025 | 18.00 (162.97%) | Beli | 8.52 |
| HC Wainwright & Co. | 23 Oct 2025 | 11.00 (60.70%) | Beli | 8.36 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2025 | Pengumuman | Novavax to Participate in Jefferies London Healthcare Conference |
| 06 Nov 2025 | Pengumuman | Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights |
| 04 Nov 2025 | Pengumuman | Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment |
| 30 Oct 2025 | Pengumuman | Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 |
| 22 Oct 2025 | Pengumuman | Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy |
| 07 Oct 2025 | Pengumuman | Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment |
| 30 Sep 2025 | Pengumuman | Novavax Announces Progress on Sanofi Agreement |
| 12 Sep 2025 | CNBC | Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |